Rezafungin Prophylaxis in Liver Transplant

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Liver Transplant InfectionFungal Infection
Interventions
DRUG

Rezafungin

Rezafungin 400 mg IV once within 24 hours of liver transplant, followed by 200 mg IV weekly for 4 weeks.

DRUG

Standard of care antifungal prophylaxis

UPMC uses a tiered approach to antifungal prophylaxis, based on risk factors for IFI. Fluconazole is used for recipients with risk factors for yeast infections: choledochojejunostomy, prolonged transplant time, receipt of \>40 units of blood products within 24 hours of transplant, and Candida colonization or infection within 3 months prior to transplant. Voriconazole is used for recipients with risk factors for mould infections: re-transplantation, renal failure requiring renal replacement therapy, fulminant hepatic failure as indication for transplant, intra-abdominal/thoracic re-exploration within the first month after transplant. No prophylaxis is given if there are no risk factors for yeast or mould infections.

Trial Locations (1)

15213

UPMC Presbyterian, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Melinta Therapeutics

INDUSTRY

lead

Fernanda P Silveira, MD, MS

OTHER